Skip to content
10-Q

Quarterly Report

COCRYSTAL PHARMA, INC. COCP

0001493152-26-023377

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 13.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.79M sh
Shares Diluted Q1 2026 · Mar 31, 2025 10.17M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.34M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.94M
Stockholders Equity Q1 2026 · Mar 31, 2026 $4.12M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.3M
Stockholders Equity Q1 2026 · Dec 31, 2024 $9.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.23M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $3.38M
Current Assets Q1 2026 · Mar 31, 2026 $5.94M
Current Assets Q1 2026 · Dec 31, 2025 $8.13M
Total Assets Q1 2026 · Mar 31, 2026 $7.43M
Total Assets Q1 2026 · Dec 31, 2025 $9.71M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.17
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.23
Eps Basic Q1 2026 · Mar 31, 2026 −$0.17
Eps Basic Q1 2026 · Mar 31, 2025 −$0.23
Sga Expense Q1 2026 · Mar 31, 2026 $1.21M
Sga Expense Q1 2026 · Mar 31, 2025 $981K
Rd Expense Q1 2026 · Mar 31, 2026 $1.37M
Rd Expense Q1 2026 · Mar 31, 2025 $1.36M
Net Income Q1 2026 · Mar 31, 2026 −$2.3M
Net Income Q1 2026 · Mar 31, 2025 −$2.3M
Operating Income Q1 2026 · Mar 31, 2026 −$2.36M
Operating Income Q1 2026 · Mar 31, 2025 −$2.34M